Opportunities like these were rare, something that wasn’t lost for a minute on Nick Giannoukakis.

Within a minute of browsing through a big drug company’s private research library, the 46-year-old diabetes researcher said he knew he was onto something big: one of the compounds could be a new way to treat diabetes, he thought.

“It was just like bingo,” Mr. Giannoukakis said. “I jumped out of my chair.”

Mr. Giannoukakis’ realization led to an unusual, two-year $2.2 million clinical trial involving rivals Allegheny Health Network and UPMC, and better ways to treat diabetes could be the result. The story began three years ago when the National Institutes of Health’s National Center for Advancing Translational Sciences began playing matchmaker between big pharmaceutical companies and independent researchers.

Advertise with us

Big Pharma develops lots of stuff that never make it to the local pharmacy checkout line for any number of reasons. The National Center for Advancing Translational Science’s goal is to give independent researchers a crack at these compounds, repurposing them for treatments that were never imagined by the drug company.

“It allows researchers to explore drug indications that pharmaceutical companies would not otherwise have the expertise to explore,” said Craig Wegner, executive director of translational services at Waltham, Mass.-based AstraZeneca Pharmaceuticals, one of eight companies that have opened their drug libraries to outside researchers. “We’ve had a very collaborative relationship.”

The compound that got Mr. Giannoukakis’ attention, dubbed AZD9668, was developed by AstraZeneca as an anti-inflammatory agent for the treatment of chronic breathing problems caused by smoking, asthma or other problems. Mr. Giannoukakis was intrigued by the drug’s anti-swelling effects because inflammation on a cellular level is associated with the onset of diabetes.

Here’s how it happens. Obesity is closely related to Type II diabetes, which affects more than 29 million Americans. Excessive body fat impairs the diabetic’s sensitivity to insulin, which is the naturally produced hormone that allows blood sugar to be absorbed and used.

For people with diabetes, cellular inflammation that accompanies obesity slowly diminishes the body’s sensitivity to insulin, leaving the patient little choice but to begin taking medications.

Advertise with us

Mr. Giannoukakis and the AHN-UPMC research team want to know if AZD9668 can stall the cellular inflammation that impairs insulin sensitivity, allowing the patient to improve eating habits and take other measures to attack the disease.

“If you can break the back of the inflammation, you can give these drugs a better chance of working,” Mr. Giannoukakis said.

AZD9668 had been shown to be safe when taken by humans and it did, in fact, reduce inflammation in animal experiments. In addition, Mr. Giannoukakis’ theory about the compound’s possible role in treating diabetes was reviewed and backed by scientists at both the NIH and AstraZeneca, Mr. Wegner said.

All that’s left is the clinical trial, which will be done in Pittsburgh and will involve 42 people who have diabetes. They will be divided into two groups and given standard diabetes medications to control the disease.

Then, half of the group will get daily doses of AZD9668 in addition to the diabetes medications. After six months, the group just getting the diabetes medicines will start taking AZD9668 with the standard diabetes medicine.

Advertise with us

“It’s a clean design, crossover study with 21 people in each group,” Mr. Giannoukakis said.

Mr. Giannoukakis is part of AHN’s Institute for Cellular Therapeutics with director Massimo Trucco. The pair left UPMC’s Children’s Hospital for AHN in 2014 along with 17 other researchers — and three espresso makers.

But their ties to UPMC have continued and two University of Pittsburgh School of Medicine doctors will be participating in the trial.

Most recently, San Diego, Calif.-based DiaVacs Inc. licensed technology from Dr. Trucco’s group to create a treatment for Type 1 diabetes.

The new research could cement AHN’s reputation as a center for innovations in treating diabetes.

Advertise with us

“We have the foundation to really lead in the treatment of diabetes,” Mr. Giannoukakis said. “This is our strength.”

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699.

Correction, posted Dec. 8, 2015: The options for patients with diminished insulin sensitivity were misstated.